Horribly busy these days so no chance to write extensively about these, but in case they are of relevance to others, here is a list of some potentially interesting reads:
eLife: Affimer proteins are versatile and renewable affinity reagents (Tiede et al.) ➡ a potential future alternative to antibodies. https://elifesciences.org/articles/24903
Nature: mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer (Zabala-Letona et al.). Quite surprised that the mechanisms only rely on inhibitor treatment (encouraging in a way if this is “all” that is required…). Mechanism suggested to be important for proliferating cells in general. https://www.nature.com/nature/journal/vaop/ncurrent/full/nature22964.html#ref6
Scientific Reports: Inhibition of ERK1/2 restores GSK3b activity and protein synthesis levels in a model of tuberous sclerosis (Pal et al.): https://pdf.nature.com/redirect-nature?ddsId=art:10.1038/s41598-017-04528-5&originUrl=https://www.nature.com/articles/s41598-017-04528-5&contentType=pdf ➡ relevant for insulin signalling via ERK. Had a quick skim of this paper. Not entirely convinced this is robust, HEK293s + MEFs used, high concentrations of insulin, drugs etc.
Scientific Reports: Direct binding of MEK1 and MEK2 to AKT induces Foxo1 phosphorylation, cellular migration and metastasis (Procaccia et al.). https://www.nature.com/articles/srep43078.pdf
British Journal of Cancer: Akt as a target for cancer therapy: more is not always better (lessons from studies in mice) (Wang et al.). Highlights how deletion of AKT2 in the liver can lead to increased cancer incidence, thus emphasising the importance of considering tissue-specific effects when inhibiting PI3K/AKT signalling in the clinic. https://www.nature.com/bjc/journal/vaop/ncurrent/pdf/bjc2017153a.pdf
American Journal of Human Genetics: 10 Years of GWAS Discovery: Biology, Function, and Translation (Visscher et al.) – it is a good read.
JCI Insight: Independent tissue contributors to obesity-associated insulin resistance (Kusters et al.) https://insight.jci.org/articles/view/89695
Cell Metabolism: How does fat transition from white to beige? (Marc L. Reitman) http://www.cell.com/cell-metabolism/fulltext/S1550-4131(17)30353-4?_returnURL=http%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1550413117303534%3Fshowall%3Dtrue ➡ a commentary on some recent surprising findings.
Cell Metabolism: Leptin’s Physiologic Role: Does the Emperor of Energy Balance Have No Clothes? (what a title; by Jeffrey Flier and Eleftheria Maratos-Flier) http://www.cell.com/cell-metabolism/fulltext/S1550-4131(17)30302-9?_returnURL=http%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1550413117303029%3Fshowall%3Dtrue
Cell: Type 2 Diabetes Variants Disrupt Function of SLC16A11 through Two Distinct Mechanisms (Rusu et al.) http://www.cell.com/cell/fulltext/S0092-8674(17)30694-3?_returnURL=http%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867417306943%3Fshowall%3Dtrue
A review in Cell: RAS Proteins and Their Regulator in Human Disease (Simanshu et al.): http://www.cell.com/cell/fulltext/S0092-8674(17)30650-5?_returnURL=http%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867417306505%3Fshowall%3Dtrue